ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Effectiveness of Yishen Tongbi decoction versus methotrexate in patients with active rheumatoid arthritis: A double-blind, randomized, controlled, non-inferiority trial

Xu, Jia; Zhang, Lu; Xu, Yanping; Yu, Jiahui; Zhao, Lianyu; Deng, Hui; Li, Meiling; Zhang, Mingying; Lei, Xujie; Hu, Congqi; Jiao, Wei; Dai, Zhao; Liu, Lijuan*; Chen, Guangxing*广州中医药大学; 1
PHYTOMEDICINE2023-4DOI: 10.1016/j.phymed.2023.154704
3被引31阅读
引用收藏
分享

摘要

Background: Yishen Tongbi decoction (YSTB) which is an herbal formula, has been used for the treatment of rheumatoid arthritis (RA) for more than ten years with a better curative effect. Methotrexate (MTX) is an effective anchoring agent used to treat rheumatoid arthritis. There were, however, no head-to-head comparative randomized controlled trials comparing traditional Chinese medicine (TCM) to MTX, Therefore, we performed this double-blind, double-model, randomized controlled trial of the efficacy and safety of YSTB and MTX in the treatment of active RA for 24 weeks. @@@ Methods: Patients who met the enrollment criteria were randomly selected (1:1) to receive either YSTB therapy (YSTB 150 ml once daily + MTX placebo 7.5-15 mg once weekly) or MTX therapy (MTX 7.5-15 mg once weekly + YSTB placebo 150 ml once daily) in treatment cycles lasting 24 weeks. The percentage of patients who achieve a clinical disease activity index (CDAI) response at week 24 is the primary efficacy outcome. A 10% risk differential non-inferiority margin was previously defined. The Chinese Clinical Trials Registry has recorded this trial (ChiCTR-1,900,024,902, registered on August 3rd 2019, http://www.chictr.org.cn/index.aspx). @@@ Results: Out of 118 patients whose eligibility was determined from September 2019 to May 2022, 100 patients (n = 50 for each group) were enrolled in the research overall. The 24-week trial was completed by 82% (40/49) of the YSTB group's patients and 86% (42/49) of the MTX group's patients. In the intention-to-treat analysis, 67.4% (33/49) of patients in the YSTB group met the main outcome of CDAI response criteria at week 24, compared to 57.1% (28/49) in the MTX group. The risk difference was 0.102 (95% CI -0.089 to 0.293), which demonstrated the non-inferiority of YSTB to MTX. After further testing for superiority, the ratio of CDAI responses achieved by the YSTB and MTX groups was not statistically significant (p = 0.298). At the same time, in week 24, secondary outcomes such as the ACR 20/50/70 response, the European Alliance of Associations for Rheumatology good or moderate response, remission rate, simplified disease activity index response, and low disease activity rate all showed similar statistically significant patterns. There was statistically significant attainment of ACR20 (p = 0.008) and EULAR good or moderate response (p = 0.009) in two groups at week 4. The intention-to-treat analysis results and the per-protocol analysis results were in agreement. The incidence of drug-related adverse events was not statistically different between the two groups (p = 0.487). @@@ Conclusions: Previous studies have used TCM as an adjunct to conventional therapy, and few of them have directly compared it with MTX. In order to lessen disease activity in RA patients, this trial demonstrated that YSTB compound monotherapy was non-inferior to MTX monotherapy and had superior efficacy following shortterm treatment. This study provided evidence-based medicine in the treatment of RA with compound prescriptions of TCM and contributed to promoting phytomedicine use in RA patients.

学科与关键词

关键词
Rheumatoid arthritisNon-inferiorityYishen Tongbi decoctionMethotrexateRandomized controlled clinical trial
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
PHYTOMEDICINE
发表日期
2023-04
卷期
第 112 卷
页码
154704
DOI
10.1016/j.phymed.2023.154704
语言
GERMAN
成果收录
SCIE
资助标注
National Natural Science Foun-dation of China [81573850]; Construction Project of Guangzhou Clinical Core Technology of Chinese Medicine

作者

  • X

    Xu, Jia (第一作者)

    1 · guangzhou univ chinese med

  • Z

    Zhang, Lu

    1 · guangzhou univ chinese med

查看全部 14 位作者收起作者
  • X

    Xu, Yanping

    1 · guangzhou univ chinese med

  • Y

    Yu, Jiahui

    1 · guangzhou univ chinese med

  • Z

    Zhao, Lianyu

    1 · guangzhou univ chinese med

  • D

    Deng, Hui

    1 · guangzhou univ chinese med

  • L

    Li, Meiling

    1 · guangzhou univ chinese med

  • Z

    Zhang, Mingying

    1 · guangzhou univ chinese med

  • L

    Lei, Xujie

    1 · guangzhou univ chinese med

  • H

    Hu, Congqi

    1 · guangzhou univ chinese med

  • J

    Jiao, Wei

    1 · guangzhou univ chinese med

  • D

    Dai, Zhao

    1 · guangzhou univ chinese med

  • L

    Liu, Lijuan (通讯)

    1 · guangzhou univ chinese med

  • C

    Chen, Guangxing (通讯)

    1 · guangzhou univ chinese med

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417